FDA expands Pfizer’s HYMPAVZI approval

Broadening access for children & patients with inhibitor-complicated hemophilia

Mariska Hargitay launches Bristol Myers Squibb's Myeloma Awareness Campaign

The campaign places renewed focus on a disease that remains incurable despite major scientific advances

Lilly’s “triple agonist” drug delivers striking weight loss & broad health gains in late-stage trials

Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems

Lupin partners with LABORATORIOS ERN to launch Luforbec in Spain

Collaboration combines Lupin’s inhaler manufacturing capabilities with ERN’s strong commercial presence to expand access to respiratory care

FUJIFILM reshapes life sciences leadership to accelerate cell therapy and iPSC expansion

Tomoyuki Hasegawa has been appointed CEO of FUJIFILM Biotechnologies California

Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials

Wegovy pill smashes past 3mn prescriptions in under six months in US

The company said Wegovy hit its first one million prescriptions within 12 weeks of availability

Pfizer reports strong mid-stage results for monthly GLP-1 drug berobenatide

The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format

Ayushman Bharat achieves full national coverage as West Bengal gets onboard

Nearly 1.43 crore families in West Bengal to benefit as India’s flagship health assurance scheme achieves full national coverage across all States and Union Territories

AstraZeneca reports major Phase III breakthrough in IgA kidney disease trial

At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint